A Systematic Review of Maternal Serum Syndecan-1 and Preeclampsia

• Published in: Curēus (Palo Alto, CA) Vol. 14; no. 6; p. e25794
• Main Authors: George, Kitty, Poudel, Prakar, Chalasani, Roopa, Goonathilake, Mastiyage R, Waqar, Sara, George, Sheeba, Jean-Baptiste, Wilford, Yusuf Ali, Amina, Inyang, Bithaiah, Koshy, Feeba Sam, Mohammed, Lubna
• Format: Journal Article
• Language: English
• Published: United States Cureus Inc 09.06.2022; Cureus
• Subjects: Bias; Biomarkers; Body mass index; Cross-sectional studies; Data collection; Edema; Family/General Practice; Heparan sulfate; Hypertension; Keywords; Observational studies; Obstetrics/Gynecology; Pathology; Preeclampsia; Pregnancy; Search engines; Search strategies; Source studies; Systematic review; Variables; Womens health; eph complex; preeclampsia; syndecan-1; cd-138; sdc-1
• ISSN: 2168-8184; 2168-8184
• DOI: 10.7759/cureus.25794

Exploration of novel biomarkers has been gaining popularity in preeclampsia, which is currently being diagnosed based on clinical criteria alone. Soluble syndecan-1, released from one of the proteoglycans associated with the syncytiotrophoblastic layer of the placenta, is affected in patients with abnormal placentation. This article is the first systematic literature review that evaluates the relationship between the antepartum serum levels of the syndecan-1 and preeclampsia. Eight studies were selected after screening and quality appraisal, and data were analyzed. The serum concentration of syndecan-1 was found to correlate positively with the gestational age in all pregnancies and negatively with the systolic blood pressure in patients with preeclampsia. Extremely low levels of soluble syndecan-1 may be helpful as a predictor for the development of preeclampsia during gestation.